Amgen (AMGN) Q3 2024 Earnings
AMGN·Reported October 30, 2024·After market close
Amgen reported Q3 2024 revenue of $8.5B, beat analyst consensus of $8.5B by $4.7M. Diluted EPS came in at $5.58, beat the $5.11 consensus by $0.47. Amgen reports across 1 business segment, led by Human Therapeutics.
Revenue
$8.5Bbeat by $4.7M
Consensus: $8.5BDiluted EPS
$5.58beat by $0.47
Consensus: $5.11
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Amgen's Q3 2024 earnings report.
Amgen (AMGN) reported Q3 2024 earnings on October 30, 2024 after market close.
Amgen reported revenue of $8.5B and diluted EPS of $5.58 for Q3 2024.
Revenue beat the consensus estimate of $8.5B by $4.7M. EPS beat the consensus estimate of $5.11 by $0.47.
You can read the 10-Q periodic report (0000318154-24-000044) directly on SEC EDGAR. The filing index links above go to sec.gov.